{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:33:56Z","timestamp":1786988036335,"version":"build-2736575974"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T00:00:00Z","timestamp":1636416000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014382","name":"Ipsen Pharma SA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.ejca.2021.10.033","type":"journal-article","created":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T00:14:40Z","timestamp":1639440880000},"page":"128-137","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Excessive toxicity of cabozantinib in a phase II study in patients with recurrent and\/or metastatic salivary gland cancer"],"prefix":"10.1016","volume":"161","author":[{"given":"Wim","family":"van Boxtel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0269-5849","authenticated-orcid":false,"given":"Maike J.M.","family":"Uijen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4406-7149","authenticated-orcid":false,"given":"Stefanie D.","family":"Krens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Dijkema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan M.","family":"Willems","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne A.","family":"Jonker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sjoert A.H.","family":"Pegge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana C.H.","family":"van Engen-van Grunsven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla M.L.","family":"van Herpen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2021.10.033_bib1","first-page":"1","article-title":"Cancer incidence in five continents. Volume VIII","year":"2002","journal-title":"IARC Sci Publ"},{"key":"10.1016\/j.ejca.2021.10.033_bib2","series-title":"WHO classification of head and neck tumours","author":"El-Naggar","year":"2017"},{"key":"10.1016\/j.ejca.2021.10.033_bib3","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/cncr.23165","article-title":"Late recurrence from salivary gland cancer: when does \u201ccure\u201d mean cure?","volume":"112","author":"Chen","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2021.10.033_bib4","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S1470-2045(10)70245-X","article-title":"Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review","volume":"12","author":"Laurie","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.10.033_bib5","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1200\/JCO.18.01859","article-title":"Phase II study of lenvatinib in patients with progressive, recurrent or metastatic adenoid cystic carcinoma","volume":"37","author":"Tchekmedyian","year":"2019","journal-title":"J Clin Oncol \u2013 Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2021.10.033_bib6","doi-asserted-by":"crossref","first-page":"6026","DOI":"10.1200\/JCO.2018.36.15_suppl.6026","article-title":"Phase II trial of apatinib in patients with recurrent and\/or metastatic adenoid cystic carcinoma of the head and neck: updated analysis","volume":"36","author":"Zhu","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.10.033_bib7","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/annonc\/mdx771","article-title":"A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma","volume":"29","author":"Fushimi","year":"2018","journal-title":"Ann Oncol \u2013 Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ejca.2021.10.033_bib8","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1200\/JCO.18.00545","article-title":"Phase II trial of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2-positive salivary duct carcinoma","volume":"37","author":"Takahashi","year":"2019","journal-title":"J Clin Oncol \u2013 Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2021.10.033_bib9","doi-asserted-by":"crossref","first-page":"102069","DOI":"10.1016\/j.ctrv.2020.102069","article-title":"Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: a systematic review","volume":"89","author":"Uijen","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2021.10.033_bib10","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.10.033_bib11","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.10.033_bib12","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","article-title":"Cabozantinib in progressive medullary thyroid cancer","volume":"31","author":"Elisei","year":"2013","journal-title":"J Clin Oncol \u2013 Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2021.10.033_bib13","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1080\/15384047.2015.1030554","article-title":"Analysis and significance of c-MET expression in adenoid cystic carcinoma of the salivary gland","volume":"16","author":"Bell","year":"2015","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.ejca.2021.10.033_bib14","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx374.003","article-title":"1046PDOverexpression of the c-MET proto-oncogene in salivary duct carcinoma patients","volume":"28","author":"Herpen","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.10.033_bib15","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.humpath.2018.04.027","article-title":"The implications of TrkA and MET aberrations in de novo salivary duct carcinoma","volume":"81","author":"Ryu","year":"2018","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ejca.2021.10.033_bib16","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1034\/j.1600-0714.2003.00018.x","article-title":"Hepatocyte growth factor and c-Met (HGF\/c-Met) in adenoid cystic carcinoma of the human salivary gland","volume":"32","author":"Suzuki","year":"2003","journal-title":"J Oral Pathol Med"},{"key":"10.1016\/j.ejca.2021.10.033_bib17","first-page":"7334","article-title":"Expressions of nuclear factor kappaB, inducible nitric oxide synthase, and vascular endothelial growth factor in adenoid cystic carcinoma of salivary glands: correlations with the angiogenesis and clinical outcome","volume":"11","author":"Zhang","year":"2005","journal-title":"Clin Cancer Res \u2013 Off J Am Assoc Canc Res"},{"key":"10.1016\/j.ejca.2021.10.033_bib18","first-page":"228","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Canc (Oxford, England : 1990)"},{"key":"10.1016\/j.ejca.2021.10.033_bib19","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1634\/theoncologist.2017-0552","article-title":"Cabozantinib in patients with advanced Merkel cell carcinoma","volume":"23","author":"Rabinowits","year":"2018","journal-title":"Oncol"},{"key":"10.1016\/j.ejca.2021.10.033_bib20","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.eururo.2018.11.033","article-title":"Cabozantinib versus mitoxantrone-prednisone in symptomatic metastatic castration-resistant prostate cancer: a randomized phase 3 trial with a primary pain endpoint","volume":"75","author":"Basch","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejca.2021.10.033_bib21","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1200\/JCO.2015.65.5597","article-title":"Phase III study of cabozantinib in previously treated metastatic castration-resistant prostate cancer: COMET-1","volume":"34","author":"Smith","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.10.033_bib22","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S1470-2045(16)30107-3","article-title":"Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial","volume":"17","author":"Choueiri","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.10.033_bib23","series-title":"Cabometyx prescribing information","year":"2020"},{"key":"10.1016\/j.ejca.2021.10.033_bib24","series-title":"Cometriq prescribing information","year":"2020"},{"key":"10.1016\/j.ejca.2021.10.033_bib25","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrclinonc.2009.94","article-title":"Adverse effects of anticancer agents that target the VEGF pathway","volume":"6","author":"Chen","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2021.10.033_bib26","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/annonc\/mdr522","article-title":"A phase II study of sunitinib in recurrent and\/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in","volume":"23","author":"Chau","year":"2012","journal-title":"ACC. Annal Oncol \u2013 Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ejca.2021.10.033_bib27","first-page":"158","article-title":"A phase II study of sorafenib in recurrent and\/or metastatic salivary gland carcinomas: translational analyses and clinical impact","volume":"69","author":"Locati","year":"2016","journal-title":"Eur J Canc (Oxford, England : 1990)"},{"key":"10.1016\/j.ejca.2021.10.033_bib28","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1093\/annonc\/mdw287","article-title":"A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma","volume":"27","author":"Ho","year":"2016","journal-title":"Ann Oncol \u2013 Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ejca.2021.10.033_bib29","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1002\/cncr.30537","article-title":"Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: a multicenter phase 2 study (Korean Cancer Study Group HN14-01)","volume":"123","author":"Kim","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2021.10.033_bib30","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1002\/hed.25891","article-title":"Phase II trial with axitinib in recurrent and\/or metastatic salivary gland cancers of the upper aerodigestive tract","volume":"41","author":"Locati","year":"2019","journal-title":"Head Neck"},{"key":"10.1016\/j.ejca.2021.10.033_bib31","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/hed.23577","article-title":"Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck","volume":"37","author":"Thomson","year":"2015","journal-title":"Head Neck"},{"key":"10.1016\/j.ejca.2021.10.033_bib32","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/annonc\/mdv537","article-title":"Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors","volume":"27","author":"Wong","year":"2016","journal-title":"Ann Oncol \u2013 Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ejca.2021.10.033_bib33","doi-asserted-by":"crossref","first-page":"21161","DOI":"10.1074\/jbc.M113.474619","article-title":"Lactate engages receptor tyrosine kinases Axl, Tie2, and vascular endothelial growth factor receptor 2 to activate phosphoinositide 3-kinase\/Akt and promote angiogenesis","volume":"288","author":"Ruan","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ejca.2021.10.033_bib34","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1083\/jcb.200701086","article-title":"c-Met is essential for wound healing in the skin","volume":"177","author":"Chmielowiec","year":"2007","journal-title":"J Cell Biol"},{"key":"10.1016\/j.ejca.2021.10.033_bib35","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1158\/1078-0432.CCR-13-2620","article-title":"Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET","volume":"20","author":"Xiang","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2021.10.033_bib36","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1002\/cncr.30571","article-title":"A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma","volume":"123","author":"Goyal","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2021.10.033_bib37","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1634\/theoncologist.2016-0229","article-title":"Phase II and biomarker study of cabozantinib in metastatic triple-negative breast cancer patients","volume":"221","author":"Tolaney","year":"2017","journal-title":"The oncologist"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921011916?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921011916?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:34:48Z","timestamp":1760733288000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804921011916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":37,"alternative-id":["S0959804921011916"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.10.033","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Excessive toxicity of cabozantinib in a phase II study in patients with recurrent and\/or metastatic salivary gland cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.10.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}